Skip to main content
Premium Trial:

Request an Annual Quote

NIH Offers SBIR Commercialization Assistance

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The National Institutes of Health is offering its Small Business Innovation Research Phase II awardees a program to provide advice and consulting on how to commercialize their products and services.

The Commercialization Assistance Program (CAP) for SBIR awardees is aimed at helping small, early-stage biomedical technology companies evaluate their options and strategies for getting their products to market.

The program provides assistance to SBIR Phase II awardees to assess their needs and prospects for winning investments, developing strategic partnerships or licensing programs, and developing a market-entry plan over an 18-month period.

"The assistance rendered under CAP is practical, oriented to addressing gaps that exist in your current commercialization status, and will allow a company to fully articulate a compelling case for market channels relevant to your business and to develop a clear understanding of potential customers, partners, investors and competitors," NIH stated in a notice today.

The 2011-2012 CAP program, which is available to most SBIR Phase II winners who have received their grants over the past five years but not to Small Business Technology Transfer (STTR) awardees, will begin in October.

The program is being conducted through a contract with the Larta Institute, a technology commercialization hub located in Los Angeles.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.